News

Otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, is a targeted T cell immunotherapy being developed for the treatment of type 1 diabetes and other autoimmune diseases. Following preliminary

The company expects to recruit around 120 patients at approximately 20 centers in the US and Canada. The study is designed to demonstrate a reduction in plaque inflammation

Under the pact, CTI is expected to initiate a Phase III trial in US and Europe in elderly patients with relapsed or refractory acute myeloid leukemia (AML) for

GLPG0187 was developed for metastatic cancer. In the trial, Galapagos expects to involve patients with solid tumor s and patients with confirmed diagnosis of advanced, recurrent, or metastatic

The company has posted a net loss of $8,929,000 for the third quarter 2011, or $0.14 loss per diluted share, compared to net loss of $1,538,000, or $0.03

The company said that $30,000 grant has been awarded to Globe Laboratories, the licensor of the technology for this year and can be increased upon completion of preliminary

FDA’s decision is supported by the identification of deficiencies in the conduct and design of the bioequivalence study which was submitted by the company in support of Pseudoephedrine

As per the terms of the offer, Elanco would acquire products, manufacturing licenses, distribution rights and the existing contract portfolio, as well as the related intellectual property and

Upon recruitment, patients will be placed in one of four dose-escalating cohorts. Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in